Rilonacept to Improve Artery Function in Patients With Atherosclerosis
Study Details
Study Description
Brief Summary
This study will determine whether an experimental drug called Rilonacept can improve artery function in patients with atherosclerosis, a disease in which fatty deposits in arteries cause the vessels to stiffen, impeding blood flow. Atherosclerosis is believed to be caused in part by inflammation. Rilonacept blocks production of a protein called CRP, which, in high levels in the blood is associated with increased inflammation. Patients with coronary artery disease who have elevated blood levels of CRP are at increased risk of heart attack, heart failure and sudden death compared with people who have lower levels of the protein.
Patients 18 years of age and older with atherosclerotic coronary artery disease with a CRP level between 2 and 10 mg/L may be eligible for this study.
Patients are randomly assigned to receive four doses of either Rilonacept or placebo, given at 2-week intervals as injections under the skin. In addition to treatment, patients undergo the following procedures during eight visits to the NIH Clinical Center:
-
Visit 1 (screening visit): Medical history, measurement of vital signs (temperature, blood pressure, heart rate and breathing rate), electrocardiogram (EKG) and blood tests.
-
Visit 2: Blood tests, chest X-ray, treadmill exercise testing, tuberculin skin test, brachial artery flow-mediated dilation. Brachial artery flow-mediated dilation is used to measure how well the brachial artery (artery inside the elbow) dilates. An ultrasound device placed just above the elbow measures the size of the brachial artery and the flow of blood through it before and after a pressure cuff is inflated around the forearm.
-
Visit 3: Injection of study drug.
-
Visits 4, 5, and 6: Review of any changes in health or medical treatment, measurement of vital signs, blood tests, EKG, injection of study drug.
-
Visit 7: Review of any changes in health or medical treatment, measurement of vital signs, blood tests, EKG, treadmill exercise testing, brachial artery flow-mediated dilation.
-
Visit 8: Review of any changes in health or medical treatment, measurement of vital signs, blood tests, EKG, treadmill exercise testing, brachial artery flow-mediated dilation.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
Rilonacept (Interleukin-1 Trap) has been developed as an antagonist of the cytokine IL-1 in the treatment of rheumatoid arthritis and other inflammatory diseases. IL-1 causes leukocyte accumulation by inducing adhesion receptors on vascular endothelium and stimulating chemokine production. It also stimulates the synthesis of other cytokines, including IL-6, which in turn stimulates synthesis of C-reactive protein (CRP) in the liver. Based on numerous clinical studies, CRP has emerged as a risk marker for the development and clinical expression of atherosclerotic cardiovascular disease, leading to published recommendations for measurement of CRP in screening population subsets for cardiovascular risk. Endothelial function, as evidenced by stimulated nitric oxide release, has also been recognized as a marker of cardiovascular disease risk. Thus, patients with coronary artery disease (CAD) or its risk factors have impaired nitric oxide release from the endothelium compared with healthy subjects. Recent studies have shown that CRP levels were significantly higher in CAD patients compared with healthy subjects, with an inverse correlation between forearm blood flow responses to acetylcholine as a measure of endothelial function and CRP. Endothelial progenitor cells (EPCs) are primitive bone marrow-derived cells that have a capacity to home to sites of vascular injury and differentiate into vascular cell types, and are reduced in number and differentiation capacity in CAD patients relative to healthy subjects. Studies suggest that CRP inhibits viability and endothelial differentiation capacity of EPCs and may account for reduced numbers of EPCs and endothelial dysfunction in CAD patients. The objective of the present study is to demonstrate the potential of an investigational biological agent, rilonacept, as adjunctive treatment for CAD by examining effects of this agent on CRP levels, endothelial progenitor cell mobilization and endothelial function in a randomized, double-blind, placebo-controlled phase I/II clinical trial.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Rilonacept Rilonacept 320 mg subcutaneous at each treatment visit |
Drug: Rilonacept
Lyophilized rilonacept will be supplied by Regeneron Pharmaceuticals at 160 mg/vial and reconstituted with 2.3 mL of sterile water for injection by the Clinical Center Pharmacy Intravenous Admixture Unit. The formulation contains 80 mg/mL rilonacept, histidine, citrate, PEG 3350, polysorbate 20, glycine, arginine, and sucrose (pH 6.5). Matching placebo in the identical formulation will also be supplied, and also reconstituted with 2.3 mL of sterile water for injection. Each administration of study drug will consist of two syringes containing 2.0 mL in each syringe (320 mg total drug).
Other Names:
|
Sham Comparator: Placebo Normal saline subcutaneously at each treatment visit. |
Drug: Placebo
Normal saline subcutaneously at each treatment visit.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- C-Reactive Protein (CRP) [2 wks following last drug administration]
C-reactive protein levels in subjects randomized to rilonacept versus placebo injections.
Other Outcome Measures
- Brachial Artery Flow-mediated Dilation [Two weeks following final administration of drug]
Brachial artery flow-mediated dilation in respone to 5 minutes of forearm ischemia
Eligibility Criteria
Criteria
-
INCLUSION CRITERIA:
-
Male and non-pregnant female subjects over 18 years of age
-
Diagnosis of atherosclerotic CAD by coronary angiography
-
High sensitivity C-reactive protein (hsCRP) between 2.0 and 10.0 g/L, inclusive with percent change in CRP from Visit 1 to Visit 2 of less than 50% to +100%.
-
Taking a HMG-CoA reductase inhibitor -For men and women of childbearing potential, willingness to utilize adequate contraception
-
Willing, at time of study enrollment, to return for all clinic visits specified in the protocol and complete all study-related procedures.
EXCLUSION CRITERIA:
-
BMI (body mass index) greater than 49.9 kg/m2 at Screening Visit 1 -Vascular intervention within 60 days prior to Screening Visit 1.
-
Infection, use of systemic antibiotics, or clinically significant trauma (including surgery) within 30 days prior to Screening Visit 1.
-
History or evidence of acute coronary syndrome within 60 days prior to Screening Visit
-
Acute or chronic inflammatory condition other than atherosclerosis
-
Recently diagnosed diabetes mellitus
-
Clinical evidence of congestive heart failure NYHA Class III-IV
-
History of hypersensitivity other than localized injection site reaction to any biologic agent.
-
Use of a thiazolidinedione
-
Use of immunosuppressive or immunomodulatory medication (use of an inhaled glucocorticoid is permitted).
-
Prior use of an immunomodulatory biologic drug within the last 6 months except immunizations and biologics used as standard care in cardiac care settings.
-
Received a live/live attenuated vaccine within 90 days prior to Screening Visit 1 or other immunization within 30 days prior to Screening Visit 1.
-
Prior or planned organ transplant recipient.
-
Severe respiratory disease
-
A history of tuberculosis infection, history of a positive skin test for tuberculosis, or a chest radiograph at Screening Visit 1 consistent with prior tuberculosis infection
-
Positive result (5 mm or more in duration at 48 to 72 hours post-placement) of the PPD 5 TU placed at Screening Visit 2
-
History or presence of malignancy (except for successfully treated basal cell carcinoma of the skin or in situ carcinoma of the cervix) within the past 5 years.
-
HIV positive.
-
Hepatitis B surface antigen or Hepatitis C antibody positive
-
ALT, AST or alkaline phosphatase greater than twice the upper limit of the normal range, serum creatinine or total bilirubin greater than 1.5 times the upper limit of normal at Screening Visit 1.
-
Hemoglobin less than 11.0 gm/dL, white blood cell (WBC) count less than 3,000/mm3, neutrophil count less than 2000/mm3 or platelet count less than 100,000/mm3 at Screening Visit 1.
-
Participation in any clinical research study evaluating another investigational drug or therapy within 30 days prior to Screening Visit 1.
-
History of substance abuse
-
Elective surgery or vascular intervention planned to occur during the study.
-
Any medical condition which would interfere with participation in the study, interfere with interpretation of study outcome measures, or place the subject at risk.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland | United States | 20892 |
Sponsors and Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
Investigators
- Principal Investigator: Richard O Cannon, MD, NHLBI, NIH
Study Documents (Full-Text)
None provided.More Information
Publications
- Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M, Giri JG, Dower SK, Sims JE, Mantovani A. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science. 1993 Jul 23;261(5120):472-5.
- Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996 Mar 15;87(6):2095-147. Review.
- Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutr. 2006 Feb;83(2):447S-455S. Review.
- 070055
- 07-H-0055
Study Results
Participant Flow
Recruitment Details | Patients with coronary artery disease were recruited from the Clinical Center outpatient clinic, and began in January, 2007. |
---|---|
Pre-assignment Detail |
Arm/Group Title | Rilonacept | Placebo |
---|---|---|
Arm/Group Description | rilonacept 320 mg injected every 2 weeks x4 administrations. | placebo injected every two weeks x 4 administrations |
Period Title: Overall Study | ||
STARTED | 4 | 6 |
COMPLETED | 4 | 6 |
NOT COMPLETED | 0 | 0 |
Baseline Characteristics
Arm/Group Title | Rilonacept | Placebo | Total |
---|---|---|---|
Arm/Group Description | rilonacept 320 mg injected every 2 weeks x4 administrations. | placebo injected every two weeks for two months | Total of all reporting groups |
Overall Participants | 4 | 6 | 10 |
Age (Count of Participants) | |||
<=18 years |
0
0%
|
0
0%
|
0
0%
|
Between 18 and 65 years |
2
50%
|
2
33.3%
|
4
40%
|
>=65 years |
2
50%
|
4
66.7%
|
6
60%
|
Age (years) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [years] |
64
(11)
|
71
(10)
|
69
(11)
|
Sex: Female, Male (Count of Participants) | |||
Female |
0
0%
|
0
0%
|
0
0%
|
Male |
4
100%
|
6
100%
|
10
100%
|
Region of Enrollment (participants) [Number] | |||
United States |
4
100%
|
6
100%
|
10
100%
|
C-reactive protein (mg/L) [Mean (Standard Deviation) ] | |||
Mean (Standard Deviation) [mg/L] |
3.6
(1.8)
|
3.9
(1.1)
|
3.8
(1.5)
|
Outcome Measures
Title | C-Reactive Protein (CRP) |
---|---|
Description | C-reactive protein levels in subjects randomized to rilonacept versus placebo injections. |
Time Frame | 2 wks following last drug administration |
Outcome Measure Data
Analysis Population Description |
---|
per protocol |
Arm/Group Title | Rilonacept | Placebo |
---|---|---|
Arm/Group Description | rilonacept 320 mg x 4 administrations over 8 weeks. | Placebo x 4 injections over 8 weeks |
Measure Participants | 4 | 6 |
Mean (Standard Deviation) [mg/L] |
3.7
(3.6)
|
4.6
(2.7)
|
Title | Brachial Artery Flow-mediated Dilation |
---|---|
Description | Brachial artery flow-mediated dilation in respone to 5 minutes of forearm ischemia |
Time Frame | Two weeks following final administration of drug |
Outcome Measure Data
Analysis Population Description |
---|
Per protocol |
Arm/Group Title | Rilonacept | Placebo |
---|---|---|
Arm/Group Description | Rilonacept 320 mg subcutaneously x4 over 8 weeks | Placebo subcutaneous injection x 4 over 8 weeks |
Measure Participants | 4 | 6 |
Mean (Standard Deviation) [percent change] |
6.3
(4.8)
|
6.5
(3.6)
|
Adverse Events
Time Frame | Two years. | |||
---|---|---|---|---|
Adverse Event Reporting Description | 81 year-old man experienced viral upper respiratory infection following the second injection of the study drug. Because of rapid resolution of symptoms, he continued to receive the final two study injections, without incident. This adverse event was reported to the DSMB, the IRB, the FDA and Regeneron on April 16, 2007. | |||
Arm/Group Title | Rilonacept | Placebo | ||
Arm/Group Description | rilonacept 320 mg injected every 2 weeks x4 administrations. | placebo injected every two weeks for two months | ||
All Cause Mortality |
||||
Rilonacept | Placebo | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
Rilonacept | Placebo | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/4 (0%) | 1/6 (16.7%) | ||
Respiratory, thoracic and mediastinal disorders | ||||
Upper respiratory infection | 0/4 (0%) | 0 | 1/6 (16.7%) | 1 |
Other (Not Including Serious) Adverse Events |
||||
Rilonacept | Placebo | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/4 (0%) | 0/6 (0%) |
Limitations/Caveats
More Information
Certain Agreements
All Principal Investigators ARE employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
Name/Title | Richard O. Cannon III, MD |
---|---|
Organization | NHLBI/NIH |
Phone | 301-496-9895 |
cannonr@nih.gov |
- 070055
- 07-H-0055